Allergan has secured approval from the US Food and Drug Administration (FDA) for its Natrelle Inspira SoftTouch breast implants.
The implants offer women undergoing breast reconstruction, augmentation or revision surgery a new medium firmness gel, or cohesive, implant option.
They have been approved for breast augmentation of women with at least 22 years old, while saline-filled implants for women with at least 18 years.
The implants will also be used for breast reconstruction, including primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality.
Last September, the firm also received FDA approval for Natrelle Inspira cohesive breast implants.
The new gummy implants, which combine high gel fill ratio and cohesive gel, will provide women with a new breast shaping option. They are available in both smooth and Biocell textured surfaces.
Allergan Chief R&D officer David Nicholson said: "Adding Natrelle Inspira SoftTouch breast implants to our already robust line of offerings gives Allergan the most extensive variety of implants in the industry and provides doctors with a wide range of options.
"Now, the Inspira line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes.
“We're delighted to have this offering available in the U.S. since they are so popular with doctors and patients internationally.